In general, patients with stable emphysema and acute exacerbation of grade I do not need special treatment, or oral treatment is sufficient. Patients with emphysema who clearly have severe infections need infusion therapy for about 7 to 14 days, and their symptoms can be significantly relieved. Emphysema is a condition in which the distal respiratory fine bronchioles of the lungs, including the respiratory fine bronchioles, alveolar ducts, and alveolar sacs, play a role in decreasing elasticity, which leads to an abnormally persistent excess of air content and overinflation. Patients may present with symptoms such as shortness of breath, cough, sputum, and shortness of breath. At present, there is no authoritative clinical data indicating how long patients with emphysema need to be infused to treat the disease. Patients with emphysema in the stable stage, acute exacerbation stage of class I, generally do not need special treatment, if there are obvious symptoms such as cough, cough sputum, shortness of breath, etc., can be appropriate use of aminoglutethimide, salbutamol and other drugs for symptomatic treatment, and at the same time, need to pay attention to changes in the condition. If the symptoms of emphysema are severe and cannot be improved by oral medication, or if there are other underlying cardiopulmonary diseases, the patient needs to receive infusion therapy for about 7-14 days, which can effectively control the development of the disease and alleviate the symptoms of the disease, thus promoting the recovery of the disease. However, some patients with spontaneous pneumothorax, subcutaneous emphysema, respiratory failure, etc. may have a relatively delayed treatment. Patients with emphysema need to take into account their own situation, actively consult the doctor, and follow the doctor’s instructions to use the medication, so as not to damage their health.